Your browser doesn't support javascript.
loading
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Mohr, Erika; Hughes, Jennifer; Reuter, Anja; Trivino Duran, Laura; Ferlazzo, Gabriella; Daniels, Johnny; De Azevedo, Virginia; Kock, Yulene; Steele, Sarah Jane; Shroufi, Amir; Ade, Serge; Alikhanova, Natavan; Benedetti, Guido; Edwards, Jeffrey; Cox, Helen; Furin, Jennifer; Isaakidis, Petros.
Afiliación
  • Mohr E; Médecins Sans Frontières, Operational Centre Brussels (OCB), Khayelitsha Project, Cape Town, South Africa.
  • Hughes J; Médecins Sans Frontières, Operational Centre Brussels (OCB), Khayelitsha Project, Cape Town, South Africa.
  • Reuter A; Médecins Sans Frontières, Operational Centre Brussels (OCB), Khayelitsha Project, Cape Town, South Africa.
  • Trivino Duran L; Médecins Sans Frontières, Operational Centre Brussels (OCB), Khayelitsha Project, Cape Town, South Africa.
  • Ferlazzo G; Médecins Sans Frontières, South African Medical Unit (SAMU), Cape Town, South Africa.
  • Daniels J; Médecins Sans Frontières, Operational Centre Brussels (OCB), Khayelitsha Project, Cape Town, South Africa.
  • De Azevedo V; City of Cape Town Health Dept, Cape Town, South Africa.
  • Kock Y; Provincial Government of the Western Cape Dept of Health, Cape Town, South Africa.
  • Steele SJ; Médecins Sans Frontières, Operational Centre Brussels (OCB), Cape Town Coordination, Cape Town, South Africa.
  • Shroufi A; Médecins Sans Frontières, Operational Centre Brussels (OCB), Cape Town Coordination, Cape Town, South Africa.
  • Ade S; Faculty of Medicine, University of Parakou, Parakou, Benin.
  • Alikhanova N; Main Medical Dept, Ministry of Justice, Baku, Azerbaijan.
  • Benedetti G; Médecins Sans Frontières, Medical Dept (Operational Research), Operational Centre Brussels (OCB), Luxembourg City, Luxembourg.
  • Edwards J; Médecins Sans Frontières, Medical Dept (Operational Research), Operational Centre Brussels (OCB), Luxembourg City, Luxembourg.
  • Cox H; Dept of Global Health, University of Washington, Seattle, WA, USA.
  • Furin J; Division of Medical Microbiology and the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Isaakidis P; Dept of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Eur Respir J ; 51(6)2018 06.
Article en En | MEDLINE | ID: mdl-29724920
Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa.This was a retrospective cohort study of patients receiving Dlm-containing treatment regimens between November 2015 and August 2017. We report 12-month interim outcomes, sputum culture conversion (SCC) by months 2 and 6, serious adverse events (SAEs) and QT intervals corrected using the Frederica formula (QTcF).Overall, 103 patients were initiated on Dlm; 79 (77%) were HIV positive. The main indication for Dlm was intolerance to second-line anti-tuberculosis (TB) drugs (n=58, 56%). There were 12 months of follow-up for 46 patients; 28 (61%) had a favourable outcome (cure, treatment completion or culture negativity). Positive cultures were found for 57 patients at Dlm initiation; 16 out of 31 (52%) had SCC within 2 months and 25 out of 31 (81%) within 6 months. There were 67 SAEs reported in 29 patients (28%). There were four instances of QTcF prolongation >500 ms in two patients (2%), leading to permanent discontinuation in one case; however, no cardiac arrhythmias occurred.This large cohort of difficult-to-treat patients receiving Dlm for rifampicin-resistant TB treatment in a programmatic setting with high HIV prevalence had favourable early treatment response and tolerated treatment well. Dlm should remain available, particularly for those who cannot be treated with conventional regimens or with limited treatment options.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazoles / Tuberculosis Pulmonar / Tuberculosis Resistente a Múltiples Medicamentos / Nitroimidazoles / Antituberculosos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Africa Idioma: En Revista: Eur Respir J Año: 2018 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazoles / Tuberculosis Pulmonar / Tuberculosis Resistente a Múltiples Medicamentos / Nitroimidazoles / Antituberculosos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Africa Idioma: En Revista: Eur Respir J Año: 2018 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido